COVID-19 vaccines developed in Seattle get the… Leave a comment

COVID-19 vaccines developed in Seattle get the green light and more – GeekWire

Structure of the UW COVID-19 vaccine (right). (YOUR PHOTO)

Two COVID-19 vaccines developed in Seattle received nods from regulators outside the United States this week. A shot from the University of Washington is ready for rollout in South Korea, and a shot attached to HDT Bio won emergency use approval in India. The UW shot is the first approved drug based on computational protein design, “For me, it’s a watershed moment,” said UW researcher Neil King told GeekWire earlier in the month.

Read on for more life science news this week in the Pacific Northwest.

Structure of a bacterial protein, including a structure produced by the open source tool OpenFold. (OpenFold image)

Clinical trials and studies:

  • Fred Hutch researcher Jesse Bloom and his colleagues have published a study outlines the main steps in the development of Omicron and other COVID-19 variants.
  • South San Francisco and Vancouver, BC-based ESSA Pharma‘s experimental therapy for prostate cancer showed “initial anti-tumor activity” in an early study.
  • The medical equipment company in the Seattle area LumiThera reported data at his trial treatment of age-related macular degeneration with some form of light therapy.
  • Black women were more likely than white women to experience delays in getting a breast biopsy than white women, according to a UW-led study. The findings suggests that systemic racism may be a factor.

Approvals and agreements:

  • Bristol Myers Squibbs CAR T-cell cancer therapy Breyanzi, manufactured in the Seattle area, was approved to treat patients at an earlier stage of disease.
  • Arzedaa company from Seattle that designs proteins for industrial use, announced a collaboration with the global materials science firm WL Gore & Associates.
  • Vancouver BC-based Poda, which developed nicotine delivery equipment, finished a sale of $ 100.5 million to Altria Group.


If you missed it:

  • Affini-T Therapeutics announced a partnership with the genre editing company Metagenomi. Affini-T, which has activities in Seattle, will use Metagenomi’s technology for its T cell receptor therapies targeting carcinogenic genes.
  • Health innovation collaboration Fabric launched an incubation program with Amazon Web Services to prepare startups from Europe, Africa and the Middle East to understand and enter the US healthcare market.

Post Views: 127


Leave a Reply